Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Howes

Showing results (391-400 of 443) with videos related to

Pageof 45
Sort By:
Molecular Psychiatry|May 13, 2021
Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET studyMaria Rogdaki, Céline Devroye, Mariasole Ciampoli, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 24, 2021
The impact of the prolonged COVID-19 pandemic on stress resilience and mental health: A critical review across wavesMirko Manchia, Anouk W Gathier, Hale Yapici-Eser, et al.
Nature Communications|January 16, 2020
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in ratsEllis Chika Onwordi, Els F Halff, Thomas Whitehurst, et al.
Schizophrenia Bulletin|January 3, 2018
Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second CohortPaul Allen, Matilda Azis, Gemma Modinos, et al.
Translational Psychiatry|March 2, 2025
The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging studyEllis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Psychopharmacology|April 20, 2011
The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET studyEuitae Kim, Oliver D Howes, Bo-Hyung Kim, et al.
Biological Psychiatry|February 9, 2025
Transcriptional and Neurochemical Signatures of Cerebral Blood Flow Alterations in Individuals With Schizophrenia or at Clinical High Risk for PsychosisSamuel R Knight, Leyla Abbasova, Yashar Zeighami, et al.
Biological Psychiatry|June 28, 2024
Mesostriatal Dopaminergic Circuit Dysfunction in Schizophrenia: A Multimodal Neuromelanin-Sensitive Magnetic Resonance Imaging and [<sup>18</sup>F]-DOPA Positron Emission Tomography StudyLuke J Vano, Robert A McCutcheon, Grazia Rutigliano, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 1, 2022
Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaborationAlice Egerton, Kira Griffiths, Cecila Casetta, et al.
Scientific Reports|July 23, 2022
A polygenic score indexing a DRD2-related co-expression network is associated with striatal dopamine functionEnrico D'Ambrosio, Giulio Pergola, Antonio F Pardiñas, et al.
Pageof 45

Showing results (391-400 of 443) with videos related to

Sort By:
Pageof 45
Molecular Psychiatry|May 13, 2021
Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET studyMaria Rogdaki, Céline Devroye, Mariasole Ciampoli, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 24, 2021
The impact of the prolonged COVID-19 pandemic on stress resilience and mental health: A critical review across wavesMirko Manchia, Anouk W Gathier, Hale Yapici-Eser, et al.
Nature Communications|January 16, 2020
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in ratsEllis Chika Onwordi, Els F Halff, Thomas Whitehurst, et al.
Schizophrenia Bulletin|January 3, 2018
Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second CohortPaul Allen, Matilda Azis, Gemma Modinos, et al.
Translational Psychiatry|March 2, 2025
The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging studyEllis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Psychopharmacology|April 20, 2011
The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET studyEuitae Kim, Oliver D Howes, Bo-Hyung Kim, et al.
Biological Psychiatry|February 9, 2025
Transcriptional and Neurochemical Signatures of Cerebral Blood Flow Alterations in Individuals With Schizophrenia or at Clinical High Risk for PsychosisSamuel R Knight, Leyla Abbasova, Yashar Zeighami, et al.
Biological Psychiatry|June 28, 2024
Mesostriatal Dopaminergic Circuit Dysfunction in Schizophrenia: A Multimodal Neuromelanin-Sensitive Magnetic Resonance Imaging and [<sup>18</sup>F]-DOPA Positron Emission Tomography StudyLuke J Vano, Robert A McCutcheon, Grazia Rutigliano, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 1, 2022
Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaborationAlice Egerton, Kira Griffiths, Cecila Casetta, et al.
Scientific Reports|July 23, 2022
A polygenic score indexing a DRD2-related co-expression network is associated with striatal dopamine functionEnrico D'Ambrosio, Giulio Pergola, Antonio F Pardiñas, et al.
Pageof 45